FDA guidance means risk regrade for two devices
This article was originally published in Clinica
Two products are now poised for reclassification by the FDA, with the publication of a final guidance on future product submissions of these devices. The products - implantable intra-aneurysm pressure management systems and hepatitis A blood tests - had previously been classified as class III (high-risk) devices, requiring manufacturers to submit costly premarket approval applications for all new products in this category. Reclassification to class II means the products can be cleared via 510(k), with fewer clinical requirements, a substantially lower user fee and review likely in 90 days or less.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.